Generate Biomedicines, Inc. (GENB)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
GENB Chart
Generate Biomedicines, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 John H. Burbank III Passport Capital LLC | 1.42M | $17.8M | $19.18M | $1.38M | 7.77% |
| MPM Mark P. Mennitt CenterBook Partners LP | 266,813 | $3.34M | $3.67M | $337,945.35 | 10.13% |
| KJ Ken Joseph Braidwel LLP | 3.59M | $44.91M | $49.15M | $4.24M | 9.44% |
 Raymond Debbane Siren, L.L.C. | 736,104 | $9.2M | $9.94M | $740,520.62 | 8.05% |
Generate Biomedicines, Inc. (GENB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Generate Biomedicines, Inc. ever had a stock split?
Generate Biomedicines, Inc. Profile
| Capital Markets Industry | Financials Sector | Michael T. Nally CEO | NASDAQ (NMS) Exchange | 370920100 CUSIP |
| US Country | 312 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Generate Biomedicines, Inc. is a pioneering company specializing in generative biology within the pharmaceutical sector, leveraging machine learning techniques for drug discovery and development. The company focuses on the programming of innovative protein therapeutics, employing protein-based modalities to advance drug development processes. With its headquarters located in Somerville, Massachusetts, Generate Biomedicines was established in 2018 and underwent a name change from Generate Biologics, Inc. to Generate Biomedicines, Inc. in February 2020. The company’s mission is to tackle therapeutic challenges that traditional technologies often cannot address, utilizing an integrative approach combining computational innovation with scalable biohardware.
Products and Services
- GB-0895: An investigational long-acting anti-TSLP monoclonal antibody currently in development specifically aimed at severe asthma treatment. This product is designed for administration every six months, offering a novel approach to managing this chronic respiratory condition.
- GB-4362: A monoclonal antibody acting as an MMAE payload neutralizer, which is developed to enhance the therapeutic effectiveness of cancer treatments by mitigating side effects and improving targeted delivery.
- GB-5267: A MUC16 CAR-T Cell therapy designed to target and eliminate tumor cells expressing the MUC16 antigen. This innovative treatment aims to enhance the body's immune response against cancer and provides a personalized therapeutic option for patients.
- Generate Platform: A cutting-edge platform that is therapeutic area and protein modality agnostic, designed to integrate computational advancements with scalable biohardware. This platform is aimed at addressing complex therapeutic challenges that exceed the capabilities of conventional technologies.
